Invitrogen Predicts Human Proteome Chip by 2006 as Revenues Rise Sharply | GenomeWeb

Invitrogen disclosed during the company’s quarterly earnings conference call last week that it paid only “some modest upfront money” for its acquisition of Protometrix, but that it was excited about the potential of the technology and expected to capitalize on a “revenue sharing approach” as Protometrix’ products make their way to the marketplace.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.